Profusa Abstract Accepted For LINC 2026; Presentation To Highlight Tissue Oxygen Monitoring Insights In PAD Pilot Study

Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients

BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany. The presentation will discuss additional insights into tissue oxygen monitoring of PAD patients from Profusa's US-based pilot clinical study on Wednesday, January 28th, 2026, 9:45am CET at the Trade Fair Leipzig, Hall 2.